Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as biomarker-wildtype tumors. They have also gained momentum not only as a treatment strategy, but as a maintenance strategy as well. While PARP inhibitors were initially ev aluated in the recurrent setting, they have now moved to frontline therapy. This review will discuss the current FDA indications of the clinically available PARP inhibitors for treatment and maintenance therapies. We will then review the recently completed and ongoing clinical trials which may inform future clinical approvals.

聚（ADP-核糖）聚合酶（PARP）抑制剂已经改变了实体瘤，特别是卵巢癌的治疗管理。最初在BRCA缺陷肿瘤中进行研究，美国食品和药物管理局 (FDA) 的适应症已扩大到包括其他同源重组缺陷肿瘤以及生物标志物野生型肿瘤。它们不仅作为一种治疗策略，而且作为一种维护策略，也获得了发展势头。虽然 PARP 抑制剂最初是在复发环境中进行评估，但现在已转向一线治疗。本综述将讨论目前 FDA 对临床可用 PARP 抑制剂用于治疗和维持治疗的适应症。然后，我们将审查最近完成和正在进行的临床试验，这可能会为未来的临床批准提供信息。